Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
0.593
-0.011 (-1.80%)
Oct 3, 2024, 4:00 PM EDT - Market closed
Amarin Corporation Revenue
Amarin Corporation had revenue of $67.49M in the quarter ending June 30, 2024, a decrease of -15.81%. This brings the company's revenue in the last twelve months to $264.78M, down -23.53% year-over-year. In the year 2023, Amarin Corporation had annual revenue of $306.91M, down -16.87%.
Revenue (ttm)
$264.78M
Revenue Growth
-23.53%
P/S Ratio
0.93
Revenue / Employee
$962,833
Employees
275
Market Cap
243.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | 429.76M | 200.54M | 87.49% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ModivCare | 2.77B |
| Procaps Group | 414.10M |
| Zynex | 193.61M |
| Nektar Therapeutics | 93.16M |
| Fulcrum Therapeutics | 81.63M |
| 2seventy bio | 44.12M |
| Mersana Therapeutics | 29.94M |
| Delcath Systems | 11.88M |
AMRN News
- 24 days ago - Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting - GlobeNewsWire
- 6 weeks ago - Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress - GlobeNewsWire
- 2 months ago - Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal - GlobeNewsWire
- 2 months ago - Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 - GlobeNewsWire
- 3 months ago - Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) - GlobeNewsWire
- 4 months ago - LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok - GlobeNewsWire